Acorda Therapeutics Announces Exercise of Option by Underwriters
Business Wire (press release) - San Francisco,CA,USA
Acorda is conducting a Phase 3 trial of Fampridine-SR to evaluate its safety and efficacy in improving walking ability in people with MS. ...
See all stories on this topic

Elan Goes to the Isles
Motley Fool - USA
Previously, Britain's National Institute for Health and Clinical Excellence had denied reimbursement of Tysabri due to its high cost and its efficacy and ...
See all stories on this topic

Biogen, Elan's Tysabri recommended by UK's NICE for highly active MS
Forbes - NY,USA
LONDON (Thomson Financial) - Biogen Idec and Elan Corp's Tysabri has been recommended for use in people with highly active relapsing remitting multiple ...
See all stories on this topic

Elan shares gain after British regulators permit Tysabri on state ...
International Herald Tribune - France
PLC rose Tuesday after British regulators approved the use of Tysabri to treat sufferers of multiple sclerosis under the state-funded National Health ...
See all stories on this topic

Elan's Tysabri gets approval by NHS
Irish Independent - Dublin,Ireland
By Ailish O'Hora THE British health regulator has overturned a previous decision and has recommended the use of Elan's multiple sclerosis treatment, Tysabri ...
See all stories on this topic

UK Group Endorses Tysabri
TheStreet.com - USA
Tysabri is the first treatment for MS the group has endorsed. NICE is an independent organization the provides guidance on how to best maintain good health ...
See all stories on this topic

UK backing for Elan's Tysabri
RTE.ie - Ireland
Pharmaceutical company Elan and its US partner Biogen say Britain's health watchdog has recommended their Tysabri drug to treat a severe form of multiple ...
See all stories on this topic

Elan/Biogen Idec: NICE green light for Tysabri in UK
Pharmaceutical Business Review - USA
By Paramjit Narang Biogen Idec's Tysabri has been given a positive recommendation by the National Institute for Clinical Excellence for multiple sclerosis, ...
See all stories on this topic

Goldman Sacks Names Teva Pharmaceuticals a Top Stock
Seeking Alpha - New York,NY,USA
On the other hand, competing Tysabri (developed by Biogen Iden) has been reinstated for use by select multiple sclerosis sufferers in Britain, ...
See all stories on this topic